Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico

23-Oct-2009 - Novavax, Inc. announced that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex is providing financial support for the trial and is expected to distribute the ...

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

28-Aug-2008 - Novavax, Inc. announced favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate ...

GE Healthcare and Novavax establish collaboration to develop and market pandemic influenza solution

Collaboration aimed at enabling vaccine production facility commissioning in half the time of a traditional egg-based facility

12-Dec-2007 - GE Healthcare, a unit of General Electric Company, and Novavax Inc. announced a collaboration agreement to develop and market a pandemic influenza vaccine manufacturing solution for selected international countries. This collaboration leverages GE Healthcare's bioprocess solutions and design ...

Novavax and Collaborators Significantly Improve VLP Vaccine for HIV/AIDS

Plans Under Way to Advance New Vaccine Into Clinical Testing

18-Jan-2007 - Novavax Inc. said that it has significantly enhanced both the quality and purity of its virus-like particle (VLP) vaccine for HIV/AIDS. Pre-clinical studies are under way using the improved HIV-1 vaccine, and planning has begun to advance the new vaccine to human clinical trials. Novavax is ...

Novavax Names Jeffrey Church Chief Financial Officer

21-Aug-2006 - Novavax, Inc. said that Jeffrey Church has been appointed Vice President, Chief Financial Officer and Treasurer, effective September 5, 2006. Mr. Church joins Novavax from GenVec, Inc., where he served as CFO, Treasurer and Corporate Secretary since 1988. During his tenure at GenVec, Mr. Church ...

Novavax Succeeds in Making Vaccine to Protect Against New Mutation of Avian Influenza

Novavax to begin pre-clinical testing immediately

02-Aug-2006 - Novavax Inc. said its scientists have succeeded in making a vaccine candidate designed to protect against the H5N1 clade 2 influenza virus. Pre-clinical testing of the vaccine has already started. "We believe this is the first vaccine to be made that targets the H5N1 clade 2 virus isolated from ...

Novavax Successfully Completes Additional Vaccine Milestone

Validation of cGMP Biological Manufacturing Facility Complete

19-Apr-2006 - Novavax, Inc. announced that it has successfully completed the renovation and validation for current "Good Manufacturing Practices" (cGMP) compliance of it's industrial facility located in Rockville, Maryland. This validation will allow production of clinical grade materials of its virus-like ...

Novavax and Bharat Biotech announce a pandemic influenza vaccine development alliance

10-Mar-2006 - Novavax, Inc. and Bharat Biotech International announced a strategic alliance to pursue the rapid development of pandemic influenza vaccine for India and other ASEAN markets. Under the terms of the Agreement, Bharat Biotech will fund all preclinical and clinical development, work with Novavax on ...